| Title |
Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial
|
|---|---|
| Published in |
Clinical Drug Investigation, September 2019
|
| DOI | 10.1007/s40261-019-00858-6 |
| Pubmed ID | |
| Authors |
Arne W. Scholtz, Ales Hahn, Bohdana Stefflova, Daniela Medzhidieva, Sergey V. Ryazantsev, Alexander Paschinin, Natalia Kunelskaya, Kai Schumacher, Gerhard Weisshaar |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 25% |
| Spain | 1 | 25% |
| Germany | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 12% |
| Student > Bachelor | 12 | 10% |
| Researcher | 9 | 8% |
| Other | 8 | 7% |
| Student > Ph. D. Student | 8 | 7% |
| Other | 17 | 15% |
| Unknown | 48 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 20% |
| Nursing and Health Professions | 14 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Neuroscience | 4 | 3% |
| Business, Management and Accounting | 3 | 3% |
| Other | 16 | 14% |
| Unknown | 52 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2023.
All research outputs
#13,860,696
of 24,205,409 outputs
Outputs from Clinical Drug Investigation
#659
of 997 outputs
Outputs of similar age
#167,430
of 352,526 outputs
Outputs of similar age from Clinical Drug Investigation
#8
of 16 outputs
Altmetric has tracked 24,205,409 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 997 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,526 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.